Atopic Dermatitis: Upadacitinib Effective in Two Phase 3 Trials ...Middle East

The JAK inhibitor, currently approved for rheumatoid arthritis, yielded improvements in skin clearance, itch, and quality of life for nearly 1700 patients with moderate to severe disease. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Atopic Dermatitis: Upadacitinib Effective in Two Phase 3 Trials )

Also on site :

• Morning Report — Texas braces for more flood danger after Hill Country tragedy 
• Bangladesh lawyers challenge ex-PM Hasina’s murder trial charges
• Ukraine plagued by ‘palace politics’ and purges – Economist